Default company panoramic image
Ca8e7653 4650 4ce9 a206 f14c201997a9

Boston 3T Biotechnologies Inc.

Boston 3T Biotechnology's technology in development is designed to cure cancer, through the use of therapeutic T Cell technology.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Woburn, MA, USA
  • Currency USD
  • Founded October 2012
  • Employees 3

Company Summary

Through our patent pending cancer technologies, we address both the humanitarian as well as the economic issues relating to cancer, both solid, as well as liquid tumors. We have passed the "discovery stage", and are ready to enter the next stage of testing . Our targeted customer will likely be a large pharmaceutical company to partner with Boston 3T Biotechnology through a licensing or sales of our technology.

Team

  • Default avatar
    Meijia Yang
    PhD

    Education and Experiences:
    Post Graduate Fellow, Stony Brook University, Stony Brook, NY
    Post Graduate Fellow, Dartmouth Medical School, Hanover, NH
    PhD in Biochemistry, University of Basel, Switzerland
    University of Freiburg, Germany , Diploma in Biology
    Member of Sino-American Pharmaceutical Professionals Association (SAPA-New England)

  • Default avatar
    Min Yang
    PhD

    Education and Membership
    Postdoctoral Fellow. Molecular Immunology, Yale School of Medicine, New Haven, CT
    Ph.D. Molecular Biology, State University of New York at Buffalo, Buffalo, NY
    B.S., Biochemistry, Fudan University, Shanghai, China
    American Association for Cancer Research (AACR)
    International Society for Biological Therapy of Cancer (iSBTC)
    The American Association of Immunologists (AAI)
    Overseas Chinese-American Entrepreneurs As

Advisors

  • Default avatar
    Foley & Hoag
    Lawyer
    Unconfirmed
    Default avatar
    Not selected as of this date
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Friends and family to date
    Unconfirmed